Fewer than a tenth of patients eligible to benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it issues its initial recommendations on the therapies.
Considering more than one billion individuals worldwide currently obese, it is advocating for increased and just availability to these injectable treatments.
According to estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The new guidelines acknowledges that excess weight is a chronic disease that can be addressed with comprehensive and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major hurdles to widespread availability to the injections that can assist patients in reducing significant body mass, notes the body.
Skinny Jab Scarcity
Despite the present most optimistic scenario, the manufacturing of such drugs could only cover around 100 million people – fewer than 10% of the global need, as stated by the health organization.
The advice calls on governments and firms to expand availability, via approaches like licensing agreements.
Exclusive production rights on the active ingredient – the core component of the drug Wegovy – is set to lapse in several nations in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, curb appetite and enhance the sense of being full so individuals consume fewer calories.
Patients usually start to lose weight in the initial weeks of beginning the regular doses.
Research suggests users may see weight return a year later of discontinuing the medication, when their normal appetite come back.
Being above a healthy weight raises your risk for contracting diseases, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns people in every country and was associated with millions of deaths worldwide in 2024, according to the health agency.
